ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s share price was down 5.2% on Tuesday . The company traded as low as $4.20 and last traded at $4.20. Approximately 1,397,000 shares were traded during mid-day trading, an increase of 1% from the average daily volume of 1,385,635 shares. The stock had previously closed at $4.43.
A number of equities analysts have recently weighed in on ZIOP shares. Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research report on Friday, November 10th. HC Wainwright reissued a “buy” rating and issued a $9.50 price objective on shares of ZIOPHARM Oncology in a research report on Tuesday, November 7th. ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Raymond James Financial reissued a “hold” rating on shares of ZIOPHARM Oncology in a research report on Monday. Finally, BidaskClub lowered shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $12.58.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. ZIOPHARM Oncology’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts predict that ZIOPHARM Oncology Inc. will post -0.54 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. Amalgamated Bank grew its stake in ZIOPHARM Oncology by 12.9% during the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,924 shares during the period. Chevy Chase Trust Holdings Inc. purchased a new stake in ZIOPHARM Oncology during the third quarter worth approximately $104,000. Oppenheimer & Co. Inc. grew its stake in ZIOPHARM Oncology by 50.0% during the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after buying an additional 6,000 shares during the period. BB&T Securities LLC purchased a new stake in ZIOPHARM Oncology during the second quarter worth approximately $112,000. Finally, Adell Harriman & Carpenter Inc. purchased a new stake in ZIOPHARM Oncology during the third quarter worth approximately $141,000. Hedge funds and other institutional investors own 40.25% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/12/12/ziopharm-oncology-ziop-trading-down-5-2.html.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.